We are adjusting our 2026 estimates for revenue to $1.5 million, from $1.8 million, and for EPS to $(2.16) from $(2.13). Focus on silicon nitride commercialization: SINTX is focused on developing silicon nitride products for medical and non-medical products in collaboration with medical/non-medical products manufacturers. SINTX believes that silicon nitride has a superb combination of properties that make it ideally suited for many medical applications. The company is now focusing and aiming for wide commercial opportunities across bio-medical industries for silicon nitride. In June 2025, SINTX acquired the surgical business assets of SiNAPTIC Holdings, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This includes (6) differentiated foot and ankle implant systems.